TRIAL SUCCESS

Lilly secures Canada-wide reimbursement pathway for Ebglyss in eczema

A pCPA letter of intent follows CDA-AMC's conditional recommendation, opening public drug-plan access nationally for a Phase 3-proven IL-13 blocker already approved by Health Canada.

By AppliedXLJuly 8, 2026Trial NCT04146363

Executive Summary

Canada's national drug reimbursement body issued a conditional positive recommendation for an IL-13-targeted eczema therapy, and the national payer alliance followed with a letter of intent that opens public drug-plan coverage across the country.
The step does not create new efficacy data; it extends the reach of a result already validated in a completed Phase 3 program and already carrying regulatory approval in multiple markets.
The Phase 3 trial behind the approval met its co-primary endpoints at Week 16 with response rates that place it inside the range of comparator IL-13 and IL-4Rα biologics, and secondary itch and quality-of-life measures also read positive.
The therapy sits in a mature, mechanism-validated field crowded with monoclonal antibodies across IL-13, IL-4Rα, IL-17, IL-23, and JAK pathways, so the reimbursement expansion matters more for patient access than for differentiating the mechanism.

The reimbursement step

Eli Lilly Canada Inc. said on July 8, 2026, that the Canadian Drug Agency (CDA-AMC) issued a positive recommendation, reimbursement with conditions, for Ebglyss in moderate-to-severe atopic dermatitis. The pan-Canadian Pharmaceutical Alliance and Lilly Canada reached a letter of intent following that recommendation, a step that precedes formal listing negotiations with provincial and territorial drug plans. Quebec's INESSS had already issued a positive recommendation on August 1, 2024, and the drug has been listed on Quebec's provincial plan (RAMQ) since then. Health Canada authorized Ebglyss on June 24, 2024, and the FDA approved lebrikizumab-lbkz for patients 12 and older with moderate-to-severe atopic dermatitis in September 2024, following a European Commission approval in 2023. Lilly

What the trial showed

The reimbursement decision traces back to ADvocate1 (NCT04146363), a Phase 3 monotherapy trial that enrolled 424 patients across the United States, Poland, Australia, South Korea, and seven other countries. The trial completed in 2022 after starting in September 2019, and it met its co-primary endpoints: up to 59% of lebrikizumab-treated patients achieved EASI-75 (at least a 75% reduction in eczema severity) and 43% achieved an Investigator Global Assessment score of 0 or 1 with at least a 2-point improvement, both at Week 16. Secondary endpoints covering itch reduction and quality-of-life measures also met their thresholds, and the trial's own safety reporting characterized the profile as established, with induction-phase serious adverse events occurring in 6 of 282 lebrikizumab-treated participants versus 1 of 141 on placebo. NCT04146363+1

Mark Kirchhof's framing

"In clinical practice, moderate-to-severe atopic dermatitis remains a challenging condition to manage, with many patients continuing to experience persistent symptoms such as itch, skin inflammation, and disruption to daily life," said Dr. Mark Kirchhof, Division Head of Dermatology at the University of Ottawa and The Ottawa Hospital, and President of the Canadian Dermatology Association. Lilly Canada General Manager Mathilde Merlet said the reimbursement decision gives physicians and patients "another treatment option in a therapeutic area with unmet need" alongside the drug's every-4-week maintenance dosing schedule after induction. Lilly

Where it sits competitively

Lebrikizumab operates as an IL-13 neutralizer, one target within the broader Type 2 cytokine family that also includes IL-4 and IL-4Rα. It is the only Phase 3 asset registered against IL-13 specifically in moderate-to-severe atopic dermatitis, though monoclonal antibodies targeting adjacent cytokine and cytokine-receptor pathways, including dupilumab (IL-4Rα), nemolizumab (IL-31RA), and amlitelimab (OX40L), compete for the same patient population. Across IL-13 x atopic dermatitis broadly, 27 Phase 3 trials have completed and 1 terminated, a 4% failure rate that marks the mechanism as largely de-risked in this indication. Sixteen active trials continue to study IL-13 in atopic dermatitis, keeping the field competitively dense even as the mechanism itself is no longer in question.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.